CN103910645B - 一种左卡尼汀化合物及其制备方法 - Google Patents
一种左卡尼汀化合物及其制备方法 Download PDFInfo
- Publication number
- CN103910645B CN103910645B CN201310003889.4A CN201310003889A CN103910645B CN 103910645 B CN103910645 B CN 103910645B CN 201310003889 A CN201310003889 A CN 201310003889A CN 103910645 B CN103910645 B CN 103910645B
- Authority
- CN
- China
- Prior art keywords
- levocarnitine
- compound
- degree
- carnitine
- crystallization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001518 levocarnitine Drugs 0.000 title claims abstract description 51
- -1 Levocarnitine compound Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 66
- 239000013078 crystal Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 229960001701 chloroform Drugs 0.000 claims description 16
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 11
- 230000008025 crystallization Effects 0.000 claims description 11
- 239000012043 crude product Substances 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 5
- 238000001757 thermogravimetry curve Methods 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 abstract description 6
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 3
- 238000013112 stability test Methods 0.000 abstract description 3
- 229960004203 carnitine Drugs 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 9
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 5
- 238000005374 membrane filtration Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- XQUKWSQHKPUBSF-UHFFFAOYSA-N C(Cl)(Cl)Cl.ClC(=O)OC=C Chemical compound C(Cl)(Cl)Cl.ClC(=O)OC=C XQUKWSQHKPUBSF-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 102000013084 Nucleotide Transport Proteins Human genes 0.000 description 1
- 108010079969 Nucleotide Transport Proteins Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- RDNPRZIJNFXCOP-UHFFFAOYSA-N [Na].C(CCCCCC)S(=O)(=O)O.O.CO Chemical compound [Na].C(CCCCCC)S(=O)(=O)O.O.CO RDNPRZIJNFXCOP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- MMFVFNVXXDFELX-UHFFFAOYSA-N chloroform;n,n-diethylethanamine Chemical compound ClC(Cl)Cl.CCN(CC)CC MMFVFNVXXDFELX-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310003889.4A CN103910645B (zh) | 2013-01-07 | 2013-01-07 | 一种左卡尼汀化合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310003889.4A CN103910645B (zh) | 2013-01-07 | 2013-01-07 | 一种左卡尼汀化合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103910645A CN103910645A (zh) | 2014-07-09 |
CN103910645B true CN103910645B (zh) | 2015-07-22 |
Family
ID=51036696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310003889.4A Active CN103910645B (zh) | 2013-01-07 | 2013-01-07 | 一种左卡尼汀化合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103910645B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009102263A (ja) * | 2007-10-24 | 2009-05-14 | Mitsubishi Rayon Co Ltd | L−カルニチンの単離精製方法 |
CN101823974A (zh) * | 2010-05-20 | 2010-09-08 | 北京科技大学 | 一种以(r)-(-)-氯代甘油为手性起始原料合成l-肉碱的制备方法 |
JP2011098934A (ja) * | 2009-11-09 | 2011-05-19 | Mitsubishi Rayon Co Ltd | L−カルニチンに含まれる不純物の除去方法 |
CN102656139A (zh) * | 2009-11-18 | 2012-09-05 | 隆萨有限公司 | 制造l-肉毒碱的方法 |
-
2013
- 2013-01-07 CN CN201310003889.4A patent/CN103910645B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009102263A (ja) * | 2007-10-24 | 2009-05-14 | Mitsubishi Rayon Co Ltd | L−カルニチンの単離精製方法 |
JP2011098934A (ja) * | 2009-11-09 | 2011-05-19 | Mitsubishi Rayon Co Ltd | L−カルニチンに含まれる不純物の除去方法 |
CN102656139A (zh) * | 2009-11-18 | 2012-09-05 | 隆萨有限公司 | 制造l-肉毒碱的方法 |
CN101823974A (zh) * | 2010-05-20 | 2010-09-08 | 北京科技大学 | 一种以(r)-(-)-氯代甘油为手性起始原料合成l-肉碱的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103910645A (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11333643B2 (en) | Identification method and content measurement method for pediatric compound Endothelium Corneum Gigeriae Galli chewable tablet | |
AnthonyáMcKervey | Selective alkali-metal cation complexation by chemically modified calixarenes. Part 4. Effect of substituent variation on the Na+/K+ selectivity in the ester series and X-ray crystal structure of the trifluoroethyl ester | |
CN102702008B (zh) | 阿戈美拉汀硫酸复合物及其制备方法 | |
CN102702041B (zh) | 阿戈美拉汀苯磺酸类复合物及其制备方法 | |
CN108047155A (zh) | 一种双芳基取代的异恶唑化合物的定向制备方法及用途 | |
EP3686203B1 (en) | 4-sulfur substituted podophyllotoxin derivative and preparation method therefor and use thereof | |
CN103804397A (zh) | 一种头孢西丁钠化合物及其制备方法 | |
CN103910645B (zh) | 一种左卡尼汀化合物及其制备方法 | |
CN102854277A (zh) | 一种妇科洗液中苦参碱含量的测定方法 | |
CN104725358A (zh) | 一种右旋雷贝拉唑钠水合物的新晶型及其制备方法 | |
Zhang et al. | Crystallization-induced dynamic resolution R-epimer from 25-OCH3-PPD epimeric mixture | |
CN107976500B (zh) | 一种双芳基取代的异恶唑化合物及其制备方法和用途 | |
CN102297905B (zh) | 用手性柱分离鉴定及制备葫芦素混合物中单体物质的hplc方法 | |
CN103910747B (zh) | 一种奥氮平药物晶型f及其制备方法 | |
CN106432274A (zh) | 一种治疗外科手术感染的药物头孢曲松钠晶体化合物 | |
BR112021014327A2 (pt) | Forma cristalina de derivado de 1,2,3-triazolo[1,5-a]pirazinas, método de preparação da referida forma cristalina, composições farmacêuticas compreendendo a mesma e seu uso | |
CN106661040A (zh) | 一种6‑芳基氨基吡啶酮甲酰胺化合物的结晶及其制备方法 | |
CN112375121B (zh) | 一种去乙酰毛花苷晶型及其制备方法 | |
CN103588695B (zh) | 一种结晶形式的奥拉西坦化合物及其制备方法 | |
CN103664889B (zh) | 一种兰索拉唑化合物 | |
Shen et al. | Detection, identification, characterization, and high‐performance liquid chromatography quantification of five impurities from a methazolamide product | |
CN104693180A (zh) | 一种雷贝拉唑钠单水合物晶型及其制备方法 | |
Guo et al. | Pharmacokinetics of tecomin in rats after intragastric and intravenous administration | |
CN103804396B (zh) | 一种盐酸头孢吡肟化合物 | |
CN106432275A (zh) | 一种制备治疗外科手术感染的药物头孢曲松钠晶体化合物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Patentee after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Patentee before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Levocarnitine Compound and Its Preparation Method Effective date of registration: 20231226 Granted publication date: 20150722 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000146 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |